Expanded Protein Panel Improves Alzheimer's Blood Test Accuracy

Researchers at the University of Gothenburg, in collaboration with international partners, have developed an enhanced blood-based diagnostic tool for Alzheimer disease that could significantly improve disease staging and streamline clinical trial recruitment. Published recently in JAMA Neurology, the study demonstrates that a multiprotein blood panel can effectively substitute for positron emission tomography imaging in assessing disease progression. Traditional Alzheimer diagnosis has long relied on observing cognitive decline, which occurs after irreversible neuronal damage has already taken place. While recent advances have introduced blood biomarkers like phosphorylated tau at position 217 to enable earlier detection, these tests struggle to accurately determine disease stage or predict progression compared to advanced imaging techniques. To address this limitation, the Gothenburg research team applied machine learning algorithms to large-scale blood proteomics data. The analysis drew from two independent international cohorts and utilized a novel immunoassay platform capable of measuring over 120 inflammation and neuronal markers in a single sample. The computational modeling successfully isolated a seven-protein signature that markedly enhances the predictive accuracy of p-tau217 for identifying advanced tau pathology in patients with elevated amyloid plaques. Guglielmo Di Molfetta, a neurochemistry doctoral student and lead researcher on the project, emphasized that this multiprotein approach could serve as a practical, cost-effective alternative to tau-PET imaging in both clinical practice and research environments. By accurately identifying late-stage disease profiles through routine blood draws, the test promises to refine patient stratification, optimize therapeutic interventions, and accelerate the recruitment pipeline for emerging Alzheimer therapies. The findings mark a pivotal shift toward accessible, scalable biomarker screening, potentially transforming how the neurodegenerative condition is monitored and treated worldwide.